Efficacy and Safety of Nivolumab in Patients with Advanced Non-small-cell Lung Cancer and Poor Performance Status.

Published on May 19, 2019in Journal of Cancer3.565
· DOI :10.7150/JCA.31217
Hideyuki Katsura1
Estimated H-index: 1
,
Hideyuki Katsura2
Estimated H-index: 2
+ 6 AuthorsHiroki Mase1
Estimated H-index: 1
Sources
Abstract
Background: Nivolumab efficacy in patients with non-small-cell lung cancer (NSCLC) and performance status (PS) of 2-4 is unclear. We aimed to compare survival, treatment efficacy, and safety in patients with NSCLC with poor PS who received nivolumab plus best supportive care (BSC) with those in patients who received BSC alone in a palliative care unit (PCU). Patients and methods: This retrospective study included 99 consecutive patients with NSCLC who received nivolumab plus BSC or BSC alone between December 2015 and March 2018. Results: In total, 43 patients with PS of 0-1 (good PS group) and 20 patients with PS of 2-4 (poor PS group) received nivolumab plus BSC; the remaining 36 patients received BSC alone in the PCU (PC group). Median overall survival was 32 days [95% confidence interval (CI), 21-43] in the poor PS group and 31 days (95% CI, 25-37) in the PC group (hazard ratio, 0.653; 95% CI, 0.368-1.158; P = 0.137). Moreover, median overall survival in patients with PS of 3 or 4 among the poor PS group was not significantly longer than that in the PC group (HR, 1.235; 95% CI, 0.646-2.360; P = 0.516). The frequency of severe pneumonitis in the poor PS group was significantly higher than that in the good PS group (25% vs. 2%, P = 0.010). Conclusion: Survival benefit of nivolumab in patients with NSCLC with poor PS, especially 3 or 4, was not confirmed. Further studies with larger numbers of patients are required to confirm our results.
References20
Newest
#1Tomoya Fukui (Kitasato University)H-Index: 16
#2Yuriko Okuma (Kitasato University)H-Index: 4
Last. Katsuhiko Naoki (Kitasato University)H-Index: 22
view all 13 authors...
Abstract Background The immune checkpoint inhibitor nivolumab is entering routine oncologic practice. We investigated the safety and efficacy of nivolumab in the real world and alternative predictive factors for survival in patients with advanced non–small-cell lung cancer (NSCLC). Patients and Methods We performed a prospective observational study to evaluate the activity of nivolumab treatment for chemotherapy-refractory NSCLC. Patients were treated with nivolumab once every 2 weeks, and the e...
42 CitationsSource
#1Rebecca L. Siegel (ACS: American Cancer Society)H-Index: 67
#2Kimberly D. Miller (ACS: American Cancer Society)H-Index: 28
Last. Ahmedin Jemal (ACS: American Cancer Society)H-Index: 139
view all 3 authors...
: Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data, available through 2015, were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data, available through 2016, were collected by the Nati...
8,491 CitationsSource
#1Hossein Borghaei (Fox Chase Cancer Center)H-Index: 49
#2Yeun Mi Yim (Genentech)H-Index: 1
Last. Raluca Ionescu-Ittu (AG: Analysis Group)H-Index: 28
view all 7 authors...
Abstract Objectives Elderly patients with advanced non-small lung cancer (aNSCLC) represent a high-risk patient population due to disease burden, comorbidities, and performance status, particularly after progressing on first-line therapy. Among elderly patients who receive second-line therapy, treatment related toxicities can have substantial impact on both clinical and economic outcomes. This study assessed the impact of severe adverse events (AEs) during second-line therapy on overall survival...
3 CitationsSource
#1Daichi FujimotoH-Index: 19
#2Hiroshige YoshiokaH-Index: 33
Last. Toyohiro Hirai (Kyoto University)H-Index: 37
view all 20 authors...
Abstract Introduction Nivolumab has been shown to be effective and safe in previously treated patients with advanced non-small cell lung cancer (NSCLC). However, little is known regarding its performance in real-world (i.e., non-trial) settings. Furthermore, nivolumab efficacy is unknown in patients who are ineligible for clinical trials or who are categorized into small subgroups in such trials. Methods We conducted a 15-center, observational, retrospective cohort study of patients with advance...
59 CitationsSource
#1Everett E. Vokes (U of C: University of Chicago)H-Index: 119
#2Neal Ready (Duke University)H-Index: 41
Last. L. CrinòH-Index: 40
view all 26 authors...
Background:Long-term data with immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) are limited. Two phase III trials demonstrated improved overall survival (OS) and a favorable safety profile with the anti-programmed death-1 antibody nivolumab versus docetaxel in patients with previously treated advanced squamous (CheckMate 017) and nonsquamous (CheckMate 057) NSCLC. We report results from ≥3 years' follow-up, including subgroup analyses of patients with liver metastases, who hist...
186 CitationsSource
Background Immunotherapy increases overall response rate (ORR) and overall survival (OS) in patients with non-small-cell lung cancer (NSCLC). Prognostic and predictive factors are a high need.
27 CitationsSource
#1Yuki KataokaH-Index: 10
#2Katsuya HiranoH-Index: 8
Last. Hiroshige Yoshioka (Kansai Medical University)H-Index: 33
view all 9 authors...
AIM: To find new predictive factors for the efficient use of immune checkpoint inhibitors in patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: In this multicenter retrospective cohort study, we evaluated consecutive patients treated with nivolumab between January and October 2016 after second-line systemic chemotherapy. The endpoint was progression-free survival (PFS), as defined by Response Evaluation Criteria in Solid Tumors version 1.1. RESULTS: A total of 189 patients w...
14 CitationsSource
#1Takayuki ShiroyamaH-Index: 15
#2Hidekazu SuzukiH-Index: 71
Last. Tomonori HirashimaH-Index: 30
view all 13 authors...
Programmed death-ligand 1 (PD-L1) expression status is inadequate for indicating nivolumab in patients with non–small cell lung cancer (NSCLC). Because the baseline advanced lung cancer inflammation index (ALI) is reportedly associated with patient outcomes, we investigated whether the pretreatment ALI is prognostic in NSCLC patients treated with nivolumab. We retrospectively reviewed the medical records of all patients treated with nivolumab for advanced NSCLC between December 2015 and May 2016...
46 CitationsSource
#1Elizabeth Dudnik (Rabin Medical Center)H-Index: 11
#2Mor Moskovitz (Rambam Health Care Campus)H-Index: 8
Last. Nir Peled (Rabin Medical Center)H-Index: 64
view all 19 authors...
Abstract Objectives Nivolumab has recently received regulatory approval as a 2nd-line treatment of non-small cell lung cancer (NSCLC). The data regarding its effectiveness and safety in real life setting is lacking. Materials and methods 260 consecutive patients with advanced NSCLC treated with nivolumab at five Israeli cancer centers between January 2015 and March 2016 were evaluated for overall survival (OS) and toxicity. OS was analyzed by the Cox proportional-hazards regression model. Overal...
52 CitationsSource
#1Takako InoueH-Index: 14
#2Motohiro TamiyaH-Index: 16
Last. Fumio ImamuraH-Index: 46
view all 15 authors...
Abstract Background The increased risk for early death due to an anti PD-1 inhibitors is a one of major disadvantage which requires special management. We evaluated the frequency, causes, and risk factors of early death during nivolumab treatment for non-small cell lung cancer (NSCLC) in Japanese clinical setting. Patients and Methods The medical records of NSCLC patients who started receiving nivolumab between December 17, 2015 and July 31, 2016 in 3 Japanese institutes were collected. Early de...
28 CitationsSource
Cited By9
Newest
BACKGROUND After the introduction of ICI treatment, data about feasibility and activity of a cetuximab-containing first-line therapy in patients with recurrent and/or metastatic head and neck cancer (R/M HNSCC) are still not available. We sought to analyze the clinical outcomes in the real-world setting. MATERIAL METHODS This retrospective study was conducted at two tertiary medical centers in Taiwan. Patients with R/M HNSCC receiving cetuximab-containing first-line therapy were included between...
Source
Abstract null null Background null Immune checkpoint inhibitors (ICIs) are standard of care in advanced non-small-cell lung cancer (NSCLC), however their status in patients with poor performance status (PS) is poorly defined. We aimed to evaluate the efficacy and safety of ICIs in NSCLC patients with PS ≥ 2. null null null Methods null We conducted a systematic review and meta-analysis of interventional and observational studies, which reported efficacy and safety data on ICIs in PS ≥ 2 comparin...
Source
#1Michael MarkH-Index: 10
#1Michael MarkH-Index: 5
Last. Martin Früh (University of Bern)H-Index: 18
view all 18 authors...
Introduction The safety of first-line (1L) durvalumab in patients with advanced nonsmall-cell lung cancer (NSCLC) and an Eastern Cooperative Oncology Group (ECOG) performance status of 2 (PS2) is unknown. This is an interim unplanned safety analysis of the study SAKK 19/17 for patients with metastatic NSCLC with programmed death-ligand 1 (PD-L1) expression in ≥ 25% of tumor cells and an ECOG PS2 treated with 1L durvalumab. This safety analysis was triggered by the SAKK data and safety monitoring...
1 CitationsSource
#1Taichi MatsubaraH-Index: 15
#2Takashi SetoH-Index: 52
Last. Tatsuro OkamotoH-Index: 31
view all 8 authors...
Purpose Anti-programmed death 1 (PD-1) antibodies have emerged as frontline treatments for patients with advanced non-small cell lung cancer (NSCLC) on the basis of global Phase III trials. However, current data regarding responses to anti-PD-1 therapy in older patients with NSCLC or those with poor performance status (PS) are limited. Therefore, we examined the therapeutic effect of anti PD-1 antibody in these patients. Patients We retrospectively examined consecutive patients treated with anti...
Source
#1Daniele Marinelli (Sapienza University of Rome)H-Index: 4
#1Daniele Marinelli (Sapienza University of Rome)H-Index: 7
Last. Paolo Marchetti (Sapienza University of Rome)H-Index: 51
view all 13 authors...
Abstract Immune-checkpoint inhibitors significantly reshaped treatment landscapes in several solid tumors. Concurrently with disease-oriented therapies, cancer patients often require proper management of drug-related adverse events and/or cancer-related symptoms. Glucocorticoids (GC) are a cornerstone of symptom management in advanced cancer care and in the management of immune-related adverse events (irAEs) due to immune-modulating therapies. Moreover, GC are often administered in patients with...
Source
#1Naoki Furuya (St. Marianna University School of Medicine)H-Index: 9
#2Koji Kojima (St. Marianna University School of Medicine)H-Index: 3
Last. Masamichi Mineshita (St. Marianna University School of Medicine)H-Index: 15
view all 11 authors...
Immune checkpoint inhibitors (ICIs) are the key drugs used in patients with non-small cell lung cancer (NSCLC). However, anti-PD-1 therapy might worsen chronic infection by reactivating the immune response to infectious diseases. Here, we describe a case of successful treatment with nivolumab in a patient with NSCLC complicated by pulmonary aspergilloma, which was safely treated by surgical resection before administration of nivolumab. In conclusion, to safely treat patients with locally limited...
Source
Lung cancer is the most common cause of cancer mortality globally. A vast majority of lung cancer cases are diagnosed at advanced stages. Management of advanced lung cancer requires several diagnostic and therapeutic procedures provided by various specialists. To optimise the entire diagnostic and therapeutic process, a concept of care provided simultaneously by a multidisciplinary team (MDT) has been developed and implemented in specialised centres worldwide. Observational studies suggest that ...
3 CitationsSource
#1Hirohisa Kano (Okayama University)H-Index: 4
#2Eiki Ichihara (Okayama University)H-Index: 21
Last. Katsuyuki Kiura (Okayama University)H-Index: 68
view all 15 authors...
Most clinical trials of non-small-cell lung cancer (NSCLC) exclude patients with poor Eastern Cooperative Oncology Group performance status (PS). Thus, the efficacy of immune checkpoint inhibitors (ICIs) in patients with poor PS remains unclear. Herein, we used data from a retrospective cohort to assess the potential clinical benefits of ICIs in NSCLC patients with poor PS. Data from NSCLC patients who received ICI monotherapy at nine institutions between December 2015 and May 2018 were retrospe...
3 CitationsSource
#2Yosuke YamamotoH-Index: 19
Last. Masahiro TakataniH-Index: 5
view all 10 authors...
Nivolumab has changed the treatment of advanced gastric cancer (AGC). Nivolumab shows better outcomes compared to best supportive care among AGC patients who received at least two prior regimens. However, there are no reliable data regarding AGC patients with poor performance status (PS) who received nivolumab. We investigated the efficacy and safety of nivolumab among AGC patients with poor PS. We retrospectively collected clinicopathologic data from patients with AGC who underwent nivolumab mo...
1 CitationsSource
#1Wei-Xin Zhao (Fudan University)
#2Yan-Lei Tang (Fudan University)
Last. Min-Wei Bao (Tongji University)
view all 4 authors...
BACKGROUND Non-small cell lung cancer (NSCLC) is the most common malignant tumor worldwide. This work focuses on investigating the role of circ_0000353 in NSCLC and its potential mechanism of action. METHODS The expression levels of circ_0000353 and miR-411-5p in NSCLC and their matched normal lung tissues were detected by real-time PCR (RT-PCR). The correlation between the circ_0000353 expression and the clinicopathological parameters of NSCLC patients was also analyzed. CCK-8, BrdU and colony ...
Source